Traduction de «will be reviewed this year » (Néerlandais → Français) :

The EU Tobacco Products Directive will be reviewed this year, and the Foundation could not miss this opportunity to bring this message to the EU decision-makers - www.cancer.be/plainpacks.
La directive européenne sur les produits du tabac doit être revue cette année ; la Fondation ne pouvait pas manquer cette occasion de répéter son message - www.cancer.be/plainpacks.

As a result, it is estimated that exceptional payments will be made over a ten-year period of up to approximately USD 418 million (CHF 453 million) depending on whether or not all current members affected by the change remain in the plan over this ten-year period.
Il s‘ensuit que des paiements exceptionnels, répartis sur une période de dix ans, pourraient atteindre USD 418 millions environ (CHF 453 millions) selon les estimations. Ce montant variera selon que tous les assurés affectés par ce changement resteront ou non soumis au plan durant cette période.

As a result, it is estimated that exceptional payments will be made over a ten-year period of up to approximately USD 463 million (CHF 453 million) depending on whether or not all current members affected by the change remain in the plan over this ten-year period.
Ces versements exceptionnels, répartis sur une période de dix ans, pourraient atteindre USD 463 millions environ (CHF 453 millions) selon les estimations. Ce montant variera selon que tous les assurés affectés par ce changement resteront ou non soumis au régime durant cette période.

2010 outlook (Barring unforeseen events) At the half-year stage we raised our sales guidance to mid- to high-single-digit in constant currency, excluding Alcon. For the full year, Group sales will include four months of Alcon and this is expected to take constant currency sales growth into the low- to mid-teens.
Perspectives 2010 (sauf événements imprévus) En milieu d’année, nous avons relevé nos objectifs de chiffre d’affaires à un taux à un chiffre dans la partie moyenne à haute de la fourchette à taux de change constants, hors Alcon Pour l’exercice complet, le chiffre d’affaires du Groupe inclura quatre mois d’Alcon ce qui devrait hisser la croissance à taux de change constants à un taux à deux chiffres dans la partie basse à moyenne de la fourchette.

Other single-pill combinations in development are a combination of aliskiren and amlodipine, currently under regulatory review in the US and Europe, and a triple-combination therapy with aliskiren, amlodipine and a diuretic, expected to be submitted for US regulatory approval this year.
D’autres médicaments combinés en un comprimé unique sont en développement, tels que aliskirène et amlodipine, actuellement en cours d’examen aux Etats-Unis et en Europe, et une trithérapie avec aliskirène, amlodipine et un diurétique qu’il est prévu de soumettre cette année pour homologation aux Etats-Unis.

A healthy diet with a variety of fresh fruit and vegetables will have many benefits and is unlikely to be harmful. It may be difficult, however, to consume as part of a normal diet the levels of antioxidants and zinc described in the trials included in this review
Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with

As part of this change, Novartis, supported by the Swiss Pension Fund, will make transitional payments, which vary according to the member’s age and years of service.
Ces changements impliquent que Novartis, soutenu par la Caisse de pensions, effectue des versements de primes de transfert qui varient en fonction de l’âge de l’assuré et des années de service.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

The Phase III program for use of this vaccine from age two months to 10 years is ongoing, and it will be expanded by 1,500 additional infants following recent discussions with the FDA.
Le programme de phase III pour l’utilisation de ce vaccin pour les âges de deux mois à dix ans est en cours. A la suite de récentes discussions avec la FDA, ce programme sera étendu à 1 500 enfants en bas âge de plus.